<DOC>
	<DOC>NCT00503009</DOC>
	<brief_summary>This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. Subjects will inhale an FDA approved virus through their nose which is known to cause the common cold. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.</brief_summary>
	<brief_title>Study Of RV-39 In Patients Who Also Have Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Have asthma for at least 3 months prior to the study. Have been using an allowed prestudy asthma therapy for at least 3 months prior to study. Demonstrate airway hyperresponsiveness following inhalation of bronchoconstrictor. Have a positive allergic status antibody test. Have a history of lifethreatening asthma. Been hospitalized for asthma within the 24 months prior to the study. Have certain conditions that would make study participation unsafe. The study doctor will evaluate other inclusion and exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rhinovirus</keyword>
	<keyword>Asthma</keyword>
</DOC>